Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/120520
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Cancer-associated fibroblasts—heroes or villains?
Author: Gieniec, K.
Butler, L.
Worthley, D.
Woods, S.
Citation: British Journal of Cancer, 2019; 121(4):293-302
Publisher: Nature Publishing
Issue Date: 2019
ISSN: 0007-0920
1532-1827
Statement of
Responsibility: 
Krystyna A. Gieniec, Lisa M. Butler, Daniel L. Worthley and Susan L. Woods
Abstract: Cancer-associated fibroblasts (CAFs) were originally presumed to represent a homogeneous population uniformly driving tumorigenesis, united by their morphology and peritumoural location. Our understanding of CAFs has since been shaped by sophisticated in vitro and in vivo experiments, pathological association and, more recently, ablation, and it is now widely appreciated that CAFs form a group of highly heterogeneous cells with no single overarching marker. Studies have demonstrated that the CAF population contains different subtypes based on the expression of marker proteins with the capacity to promote or inhibit cancer, with their biological role as accomplices or adversaries dependent on many factors, including the cancer stage. So, while CAFs have been endlessly shown to promote the growth, survival and spread of tumours via improvements in functionality and an altered secretome, they are also capable of retarding tumorigenesis via largely unknown mechanisms. It is important to reconcile these disparate results so that the functions of, or factors produced by, tumour-promoting subtypes can be specifically targeted to improve cancer patient outcomes. This review will dissect out CAF complexity and CAF-directed cancer treatment strategies in order to provide a case for future, rational therapies.
Keywords: Extracellular Matrix; Animals; Humans; Mice; Neoplasms; Neoplasm Invasiveness; Prognosis; Energy Metabolism; Phenotype; Cancer-Associated Fibroblasts
Rights: © The Author(s), under exclusive licence to Cancer Research UK 2019. This work is published under the standard license to publish agreement.
RMID: 0030120721
DOI: 10.1038/s41416-019-0509-3
Grant ID: http://purl.org/au-research/grants/nhmrc/1143414
http://purl.org/au-research/grants/nhmrc/1140236
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.